Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human kallikrein 1
- Development stage
- Phase 3
- Lead developer
- DiaMedica Therapeutics
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Recombinant human kallikrein-1 (DM199) is a biologic therapeutic being developed by DiaMedica Therapeutics. It is a recombinant version of the human tissue kallikrein-1 (KLK1) protein, a serine protease produced using Chinese hamster ovary (CHO) cells. The drug's mechanism of action involves the cleavage of low-molecular-weight kininogen to release kinins, such as bradykinin and kallidin. these kinins subsequently activate bradykinin B2 receptors, leading to localized vasodilation, improved microcirculation, and various tissue-protective effects, including anti-inflammatory, anti-apoptotic, anti-fibrotic, and antioxidative activities. DM199 is primarily being investigated for the treatment of acute ischemic stroke and chronic kidney disease, where it aims to restore the impaired kallikrein-kinin system to improve blood flow and reduce tissue damage.
- Brand names
- DM199DM-199DM 199
- Other names
- rhKLK-1rhKLK1rhKLK 1recombinant human tissue kallikrein-1
02
Targets
KNG1 (High-molecular-weight kininogen)Bradykinin B2 receptor
Beyond the preview
Go deeper on recombinant human kallikrein 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human kallikrein 1.